Identifying DNA markers to predict treatment outcomes in multiple myeloma
Official title: Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma
Funded at University of Chicago · NIH-10430121 · Data updated 2026-11-12
This study is looking at how certain changes in your DNA found in your blood can help doctors predict how well your multiple myeloma treatment will work, so they can tailor your care to better suit your needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | July 6, 2018 |
| Project end | June 30, 2025 |
| Funding year | 2022 |
| Award (this year) | $609,211 |
| NIH project number | 5R01CA223662-05 |
| Project ID | NIH-10430121 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma who are beginning treatment.
✕Less likely to help
Patients who are not diagnosed with multiple myeloma or those who have already experienced multiple relapses may not benefit from this research.
What this research studies
This research investigates how specific changes in DNA, known as epigenomic markers, found in the blood of patients with multiple myeloma can help predict treatment outcomes. By analyzing circulating cell-free DNA, the study aims to identify markers that indicate a higher risk of early relapse after treatment. This non-invasive approach could provide valuable insights at the time of diagnosis, allowing for more personalized treatment plans. The research focuses on understanding the role of different DNA modifications in the progression of multiple myeloma.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of treatment responses and improved management strategies for patients with multiple myeloma.
How similar studies have gone: Previous research has shown promise in using epigenetic markers for cancer prognosis, suggesting that this approach could be effective.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Chiu, Brian C-H — University of Chicago
- Study coordinator: Chiu, Brian C-H
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.